Universal Biosensors, Inc. (ASX: $UBI) Entitlement Offer Prospectus

Universal Biosensors, Inc. (UBI) (ASX: $UBI) has released a prospectus for a fully underwritten pro rata non-renounceable Entitlement Offer to raise up to $10.0 million. The offer includes 1 New CDI for every 3.47 Existing CDIs held by Eligible Securityholders at the Offer Price of $0.15 per New CDI, along with 1 New Option for every 1 New CDI issued, with an exercise price of $0.20. The last date for acceptance and payment under the Entitlement Offer is 5.00pm (Melbourne time) on Wednesday, 1 May 2024. The company also offers Placement Options and Underwriter Options. The Prospectus provides detailed information on the Offers, including the purpose and effect, financial information, risk factors, and additional information. The Chairman's letter provides an overview of the capital raising, the use of proceeds, and the Top Up Facility. Eligible Securityholders are invited to participate in the Entitlement Offer, and the Prospectus provides instructions for applications, payment of Application Monies, and the Top Up Facility. The company encourages investors to read the entire Prospectus before making any investment decision and to consider the risks associated with the Entitlement Offer.

Executive Commentary on Entitlement Offer

The Prospectus for the Entitlement Offer outlines our commitment to raising capital to support our strategic initiatives and growth plans. We believe that this offer presents an opportunity for our Eligible Securityholders to participate in the company's future and contribute to our continued success. The detailed information provided in the Prospectus aims to ensure transparency and clarity for all potential investors. We encourage thorough consideration of the risks and potential benefits before making any investment decisions.

Summary of Entitlement Offer and Outlook

Universal Biosensors, Inc. (UBI) has announced a prospectus for a fully underwritten pro rata non-renounceable Entitlement Offer to raise up to $10.0 million. The offer includes New CDIs, New Options, and Additional New Securities. The company aims to utilize the proceeds to support its strategic initiatives and growth plans. The Prospectus provides detailed information on the purpose and effect of the Offers, financial information, risk factors, and additional details. Eligible Securityholders are encouraged to participate in the Entitlement Offer and are advised to carefully review the Prospectus before making any investment decisions. The company's commitment to transparency and the outlined capital raising strategy reflects its dedication to fostering investor confidence and supporting its future endeavors.